Cerus Corp. (CERS)

4.13
NASDAQ : Health Technology
Prev Close 4.13
Day Low/High 0.00 / 0.00
52 Wk Low/High 1.93 / 5.43
Avg Volume 1.22M
Exchange NASDAQ
Shares Outstanding 124.41M
Market Cap 478.99M
EPS -0.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Cerus Announces Public Offering Of Common Stock

Cerus Announces Public Offering Of Common Stock

Cerus Corporation (NASDAQ: CERS) today announced that it has commenced a registered underwritten public offering of $50.

Cerus Reports Positive Top-Line Results From Chronic Anemia Phase 3 Study Evaluating INTERCEPT Red Blood Cells In Thalassemia Patients

Cerus Reports Positive Top-Line Results From Chronic Anemia Phase 3 Study Evaluating INTERCEPT Red Blood Cells In Thalassemia Patients

Cerus Corporation (NASDAQ: CERS) today reported that the primary efficacy and safety endpoints were successfully achieved in the company's Phase 3 transfusion study of chronic anemia evaluating INTERCEPT-treated red blood...

Commit To Purchase Cerus Corp. At $3, Earn 10% Using Options

Investors eyeing a purchase of Cerus Corp. stock, but cautious about paying the going market price of $4.22/share, might benefit from considering selling puts among the alternative strategies at their disposal.

Cerus Corporation Announces Preliminary Product Revenue Results For Fourth Quarter And Full Year 2017

Cerus Corporation Announces Preliminary Product Revenue Results For Fourth Quarter And Full Year 2017

Cerus Corporation (NASDAQ: CERS) today announced unaudited preliminary product revenue for the fourth quarter and full year 2017 and provided 2018 product revenue guidance.

Cerus Corporation Receives IDE Approval To Initiate Phase III ReCePI Study

Cerus Corporation Receives IDE Approval To Initiate Phase III ReCePI Study

Cerus Corporation (NASDAQ: CERS) today announced it has received an investigational device exemption (IDE) approval from the U.

Cerus Corporation Reports Third Quarter 2017 Results

Cerus Corporation Reports Third Quarter 2017 Results

Cerus Corporation (NASDAQ:CERS) today announced financial results for the third quarter ended September 30, 2017.

Cerus To Present At Two Upcoming Conferences

Cerus To Present At Two Upcoming Conferences

Cerus Corporation (NASDAQ:CERS) announced today that management will present at two upcoming investor conferences: Stephens Fall Investor Conference at the Lotte New York Palace Hotel in New York City on...

Cerus And Kedrion Biopharma Enter Distribution Agreement For The Full INTERCEPT Blood System Portfolio In Italy

Cerus And Kedrion Biopharma Enter Distribution Agreement For The Full INTERCEPT Blood System Portfolio In Italy

Cerus Corporation (NASDAQ:CERS) announced today that it has entered into an agreement with Kedrion Biopharma to distribute the full complement of INTERCEPT Blood System products in Italy.

Cerus Announces Agreement With Transfusion Center Of The Community Of Madrid

Cerus Announces Agreement With Transfusion Center Of The Community Of Madrid

Cerus Corporation (NASDAQ:CERS) announced today that it has entered into a supply agreement with Centro de Transfusión de la Comunidad de Madrid (CTCM) for the INTERCEPT Blood System for platelets.

Cerus Announces National German Reimbursement For Pathogen Inactivated Platelets

Cerus Announces National German Reimbursement For Pathogen Inactivated Platelets

Cerus Corporation (NASDAQ:CERS) announced today that the Institute for the Hospital Remuneration System (Institut für das Entgeltsystem im Krankenhaus, or InEK) in Germany will include pathogen-inactivated platelets...

Cerus To Release Third Quarter 2017 Results On November 2, 2017

Cerus To Release Third Quarter 2017 Results On November 2, 2017

Cerus Corporation (NASDAQ:CERS) announced today that its third quarter results will be released on Thursday, November 2, 2017, after the close of the stock market.

Cerus Announces First Biologics License Application Approval For U.S. Blood Center Customer

Cerus Announces First Biologics License Application Approval For U.S. Blood Center Customer

Cerus Corporation (NASDAQ:CERS) announced today that Rhode Island Blood Center received approval by the U.

Cerus Announces Schedule Of Presentations At The 2017 AABB Annual Meeting

Cerus Announces Schedule Of Presentations At The 2017 AABB Annual Meeting

Cerus Corporation (NASDAQ:CERS) announced today its schedule of key events at the AABB (formerly known as the American Association of Blood Banks) Annual Meeting to be held October 7-10 in San Diego, California.

Cerus To Present At Cantor Fitzgerald's Annual Healthcare Conference On September 27, 2017

Cerus To Present At Cantor Fitzgerald's Annual Healthcare Conference On September 27, 2017

Cerus Corporation (NASDAQ:CERS) announced today that William 'Obi' Greenman, Cerus' president and chief executive officer, is scheduled to present a corporate update at the Cantor Fitzgerald Healthcare Conference at 10:20...

Cerus To Present At Two Upcoming Conferences

Cerus To Present At Two Upcoming Conferences

Cerus Corporation (NASDAQ:CERS) announced today that William 'Obi' Greenman, Cerus' president and chief executive officer, will present at two upcoming conferences: Baird's 2017 Global Healthcare Conference...

Cerus Corporation Reports Second Quarter 2017 Results

Cerus Corporation Reports Second Quarter 2017 Results

Cerus Corporation (NASDAQ: CERS) today announced financial results for the second quarter ended June 30, 2017.

Cerus Enters Into $40 Million Amended Growth Capital Agreement

Cerus Enters Into $40 Million Amended Growth Capital Agreement

Cerus Corporation (NASDAQ:CERS) announced today that it has entered into a $40 million amended growth capital credit facility with Oxford Finance LLC, a specialty finance firm that provides senior debt to life sciences and...

Cerus Announces Expanded Supply Agreement With French National Blood Service

Cerus Announces Expanded Supply Agreement With French National Blood Service

Cerus Corporation (NASDAQ: CERS) announced today the signing of two, new, expanded contracts with Établissement Français du Sang (EFS), the French National Blood Service, for the INTERCEPT Blood System.

Cerus Announces Collaboration With Central California Blood Center To Manufacture Pathogen-Reduced Cryoprecipitate

Cerus Announces Collaboration With Central California Blood Center To Manufacture Pathogen-Reduced Cryoprecipitate

Cerus Corporation (NASDAQ:CERS) announced today an agreement with the Central California Blood Center (CCBC) in which CCBC will manufacture pathogen-reduced cryoprecipitate ("cryo") for the company.

Cerus To Release Second Quarter 2017 Results On August 3, 2017

Cerus To Release Second Quarter 2017 Results On August 3, 2017

Cerus Corporation (NASDAQ:CERS) announced today that its second quarter results will be released on Thursday, August 3, 2017, after the close of the stock market.

Commit To Purchase Cerus Corp. At $2, Earn 13.3% Annualized Using Options

Commit To Purchase Cerus Corp. At $2, Earn 13.3% Annualized Using Options

Investors eyeing a purchase of Cerus Corp. stock, but cautious about paying the going market price of $2.54/share, might benefit from considering selling puts among the alternative strategies at their disposal.

INTERCEPT Blood System Highlighted At The International Society Of Blood Transfusion (ISBT)

Cerus Corporation (NASDAQ:CERS) announced results of 16 abstracts presenting experiences with the INTERCEPT Blood System for platelets, plasma, and red blood cells during the 27 th Regional Congress of the International...

Cerus Provides Update On U.S. Platelet Additive Solution (PAS) Supply

Cerus Corporation (NASDAQ:CERS) announced today that the expected Fresenius Kabi platelet additive solution (PAS) shortage the company announced on May 23, 2017, could be less disruptive to blood center production of...

Biotech Movers: Cerus, Alexion, NantKwest

Biotech Movers: Cerus, Alexion, NantKwest

Cerus, Alexion Pharmaceuticals and NantKwest were among the biotech movers in premarket trading on Tuesday.

Cerus Provides U.S. Business Update

Cerus Corporation (NASDAQ: CERS) announced today that it received notification last week of a pending U.

First Patient Transfused In Cerus' Phase III RedeS Study Evaluating Safety And Efficacy Of The INTERCEPT Red Blood Cell System

Cerus Corporation (NASDAQ: CERS) announced today that the first patient has been transfused in Puerto Rico for the "INTERCEPT Blood System for Red Blood Cells in Regions at Potential Risk for Zika Virus...

Cerus Announces Exercise Of Additional BARDA Contract Options Totaling $46.6 Million To Support INTERCEPT Red Blood Cell System Development

Cerus Corporation (NASDAQ: CERS) announced today that additional options totaling $46.

Notable Thursday Option Activity: CERS, BZH, CATM

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Cerus Corp. , where a total volume of 3,279 contracts has been traded thus far today, a contract volume which is representative of approximately 327,900 underlying shares (given that every 1 contract represents 100 underlying shares).

TheStreet Quant Rating: D- (Sell)